In an American Antitrust Institute (AAI) White Paper issued today, AAI Vice President Diana Moss sets out the major issues involving the development of generic competition in a genetic trait for soybean tolerance to the herbicide glyphosate. One of the many competitive issues in the agriculture...

Two major changes in Brazilian legislation during the 1990s reshaped the local pharmaceutical industry: the ratification of the TRIPS agreement including a provision for pipeline inventions in 1996, and a Generic Drug Act in 1999, which introduced bioequivalence tests and facilitated generic...

Two major changes in Brazilian legislation during the 1990s reshaped the local pharmaceutical industry: the ratification of the TRIPS agreement including a provision for pipeline inventions in 1996, and a Generic Drug Act in 1999, which introduced bioequivalence tests and facilitated generic...

Brazil is renowned worldwide for its remarkable reforms in pharmaceutical regulation, which have enhanced access to essential medicines while lowering drug costs. This book innovates by analysing the generic drug reform in Brazil, demonstrating that pharmaceutical regulation is only partially...

Two major changes in Brazilian legislation during the 1990s reshaped the local pharmaceutical industry: the ratification of the TRIPS agreement including a provision for pipeline inventions in 1996, and a Generic Drug Act in 1999, which introduced bioequivalence tests and facilitated generic...